©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Adenovirus E1A Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, via Alternative Pocket Protein- and p300-binding Domains (*)

(Received for publication, December 22, 1994; and in revised form, January 24, 1995)

Lorrie A. Kirshenbaum (§) Michael D. Schneider (¶)

From the Molecular Cardiology Unit, Departments of Medicine, Cell Biology, and Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas 77030

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

To examine the potential impact of disrupting ``pocket'' protein function on cardiac differentiation and growth, we introduced 12 S E1A genes into neonatal ventricular myocytes, by adenoviral gene transfer. In the absence of E1B, E1A was cytotoxic, with features typical of apoptosis. In the presence of E1B, E1A preferentially inhibited transcription of cardiac-restricted alpha-actin promoters, and reactivated DNA synthesis in cardiac myocytes, without cell death. Mutations that abrogate known activities of the amino terminus of E1A, versus conserved region 2, demonstrate that the ``pocket'' protein- and p300-binding domains each suffice, in the absence of the other, for transcriptional repression and re-entry into S phase.


INTRODUCTION

Though the molecular events governing cell-cycle exit in cardiac muscle are cryptic at present, potential clues are available from skeletal muscle and other model systems. Mitogenic growth factors control the cell cycle in part through cyclin-dependent protein kinases, which in turn alter the phosphorylation or expression of so-called ``pocket'' proteins including the retinoblastoma gene product, Rb, (^1)p107, and p130(1, 2, 3) . Hyperphosphorylation or down-regulation of pocket proteins causes release of the transcription factor E2F, activating E2F-dependent genes needed for DNA synthesis(1) . A concurrent role for pocket proteins, as a platform for the action of myogenic transcription factors, suggests that release of myogenic factors from the pocket abrogates their function, repressing muscle-specific transcription(2, 3) .

Certain transforming proteins of DNA tumor viruses including adenovirus E1A, SV40 large T antigen, and human papilloma virus E7 physically interact with pocket proteins and can be used as surrogates for growth factors, to establish the involvement of pocket proteins in cells' growth or differentiation(1, 2, 3, 4, 5, 6, 7) . Evidence for operation of a pocket protein-dependent pathway in cardiac muscle is provided by transgenic mice that express SV40 large T antigen in myocardium, which provide a conceptual framework for our investigations(8, 9, 10) . However, large T antigen also interacts with targets distinct from pocket proteins, including the tumor suppressor p53, and systematic mutagenesis to discriminate among these is impracticable in vivo. Moreover, since the cardiac promoters used are first transcribed early in cardiogenesis, transgenic models might not predict the outcome of de novo interventions, after birth.

As a step toward identifying positive and negative regulators of myocardial growth, we have investigated the consequences of E1A proteins in neonatal ventricular myocytes, cells that still retain limited ability to respond to exogenous growth signals(11) . We chose to use E1A, given the precedent of E1A's impact on skeletal muscle (4, 5, 6) and the delineation of E1A domains for interaction with cellular targets(7, 12, 13) . Two major E1A transcripts, 13 S and 12 S, yield proteins of 289 and 243 amino acids. Conserved region (CR) 1, CR2, and CR3, shared across adenovirus serotypes, and the amino terminus are essential for protein binding and biological activity. CR3 encodes a domain for transactivation of late viral genes necessary for virus replication, absent from 12 S E1A products. One active site, for binding pocket proteins, comprises CR2 together with CR1(7, 13) ; a second, comprising the amino terminus of E1A with CR1, binds p300, a bromodomain protein with properties of a transcriptional coactivator (14) . A missense mutation of CR2 and the amino terminus, R2G,C124G, abrogates binding both to pocket proteins and p300(7, 13) , and disrupts all known E1A functions. Selective mutations that disrupt binding to pocket proteins but not p300, or vice versa, can test each pathway individually(7, 12, 13) . Finally, adenoviruses ensure virtually uniform gene transfer to cardiac myocytes, an advantage for efforts to manipulate myocyte growth itself(15) .


EXPERIMENTAL PROCEDURES

Cell Culture

Ventricular myocytes from 2-day post-natal Sprague-Dawley rats were isolated, subjected to Percoll gradient centrifugation, and cultured as described previously(16) . After overnight incubation in Dulbecco's modified Eagle's medium/Ham's nutrient mixture F-12, 1:1, 17 mM HEPES, 3 mM NaHCO(3), 2 mML-glutamine, 50 µgbulletml gentamicin, and 5% horse serum, the medium was replaced on the following day by serum-free medium containing 1 µgbulletml insulin, 5 µgbulletml transferrin, 1 nM Na(2)SeO(4), 1 nM LiCl, 25 µgbulletml ascorbic acid, and 1.0 nM thyroxine(17, 18) .

Recombinant Adenoviruses

Adenoviruses were propagated and titered using human 293 cells, were harvested by freeze-thawing, and were purified by ultracentrifugation in cesium chloride(19) . ``12 S E1A + E1B'' denotes virus 12S.WT(20) , containing the EcoRI-XbaI fragment of 12 S Ad2 E1A cDNA ligated into Ad5dl309. ``R2G + E1B,'' ``Y47H,C124G + E1B,'' and ``R2G,C124G + E1B'' designate the exact amino acid substitutions of viruses 12S.RG2, 12S.YH47/928, and 12S.RG2/928(13) . The four viruses indicated above each also confer E1B. ``12 S E1A - E1B'' indicates virus 12SE1B, containing a deletion of E1B between nucleotides 1769 and 3322(21) . CR3, which is required for transactivation of certain adenovirus early promoters and, hence, productive infection, is absent from all 12 S E1A proteins. Cells were incubated in serum-free medium for 24 h, then in serum-free medium containing virus for 6 h, and were analyzed after another 24-72 h in the absence of serum.

Assays of Apoptosis and DNA Synthesis

Live and dead cells were distinguished using 2 µM calcein acetoxymethyl ester and 2 µM ethidium homodimer-1, respectively (Molecular Probes). To visualize nuclear morphology, cardiac myocytes were identified using indirect immunofluorescence microscopy for sarcomeric myosin heavy chain (MHC) and were counterstained with Hoechst dye 33258; MF20 hybridoma supernatant (22) was used at a 1:5 dilution, followed by 10 µg/ml rhodamine-conjugated sheep F(ab)`(2) against mouse IgG (Boehringer Mannheim). Nucleosomal DNA laddering was analyzed by 1% agarose gel electrophoresis. DNA synthesis was monitored using a 4-h pulse of 10 µM 5`-bromodeoxyuridine (BrdUrd), from 44 through 48 h after infection, and was detected using mouse monoclonal antibody against BrdUrd and horseradish peroxidase-conjugated goat antibody against mouse IgG (Amersham Corp.). For immunofluorescence microscopy, fluorescein-conjugated mouse IgG(1) against BrdUrd was used at 10 µg/ml; sarcomeric MHC was visualized using MF20 and rhodamine-conjugated second antibody.

Transfection

As the transfection efficiency for cardiac myocytes was found to decrease on later days in culture, cells were infected with recombinant adenovirus 18-24 h after plating and were transfected immediately after removal of the viral stocks. Cells were incubated for 1 h with the DNA-DEAE-dextran complex, containing 2.5 µg of a cytomegalovirus promotor-driven E. coli beta-galactosidase plasmid, 5 µg of a luciferase reporter gene, and 2.5% calf serum, then were incubated for 60 s with 10% dimethyl sulfoxide in Dulbecco's modified Eagle's medium(16, 23, 24) . Cells were maintained in the serum-free medium described above and were harvested 48 h after transfection. Constructs driven by the skeletal alpha-actin, cardiac alpha-actin, and herpes simplex virus thymidine kinase promoters were detailed previously(16, 24) . The cytoplasmic beta-actin reporter gene comprised nucleotides -433 to +61 of the avian beta-actin promoter(25) , cloned into the HindIII site of pGL2 (Promega). Luciferase and lacZ activity were monitored as described(16) . Results were compared by Scheffe's multiple comparison test for analysis of variance and the unpaired two-tailed t test, using a significance level of p < 0.05.


RESULTS AND DISCUSSION

Preliminary plasmid transfections revealed dose-dependent repression of skeletal and cardiac alpha-actin promoters by wild type 12 S E1A, and not R2G,C124G(^2); however, inhibition of constitutive promoters was equivalent in extent, suggesting a generalized phenomenon. Although little attention was given to programmed cell death in connection with E1A in striated muscle, recently it has become appreciated that E1A unaccompanied by E1B can lead to apoptosis(26) . To test whether these pilot results were confounded by the absence of E1B, we transfected cardiac myocytes with the skeletal actin reporter, 12 S E1A, and increasing concentrations of E1B expression vector.^2 E1B itself had no effect on the skeletal actin promoter but partially restored E1A-inhibited transcription (p < 0.01). Thus, repression by E1A was due in part to the absence of E1B, and hence, potentially, apoptosis.

To circumvent this impediment, we employed recombinant adenoviruses that coexpress 12 S E1A in tandem with E1B. Except where noted, cultures were incubated with 20 plaque-forming units/cell, from 24 to 30 h after plating, and were maintained in serum-free medium(18) . This multiplicity of infection achieves gene delivery to geq95% of neonatal ventricular cells.^2

To verify that E1A provokes cardiac myocyte death in the absence of E1B, ventricular myocytes were stained 24-72 h after infection with calcein acetoxymethyl ester and ethidium homodimer-1 to mark live and dead cells, respectively (Fig. 1). At 24 h, cells infected with 12 S E1A + E1B or R2G,C124G + E1B were indistinguishable from uninfected cells; 12 S E1A - E1B increased cell death 4-5-fold (p < 0.01). Likewise, cell death at 72 h did not differ significantly between uninfected cells and those infected with 12 S E1A + E1B (p = 0.44), whereas cell death was increased 5-fold by 12 S E1A - E1B (p = 0.002, versus uninfected cells). To confirm that E1A in the absence of E1B was cytotoxic for cardiac myocytes themselves, we utilized indirect immunofluorescence for sarcomeric MHC (22) and Hoechst dye 33258 for nuclear DNA. No difference from uninfected cells was seen with 12 S E1A + E1B (Fig. 2, A-F; Table 1). By contrast, cardiac myocytes infected with 12 S E1A - E1B showed cell rounding and disruption of nuclear DNA (Fig. 2, G-I). To corroborate that apoptosis was the mechanism of cell death induced by E1A, we tested for nucleosomal DNA fragmentation (Fig. 2J). Laddering was induced by 12 S E1A - E1B, but not 12 S E1A + E1B, consistent with the proportions of live and dead cells.


Figure 1: E1A, in the absence of E1B, induces cell death in cardiac myocytes. After infection, cells cultured for 24 (A-D) or 72 (E and F) h (18) were visualized using calcein acetoxymethyl ester (green) versus ethidium homodimer-1 (red). A, uninfected cells; B, R2G,C124G + E1B; C and E, 12 S E1A + E1B; D and F, 12 S E1A - E1B. Bar, 80 µm. Lower panel, results at 24 h were calculated using geq200 cells for each condition shown.




Figure 2: E1A-induced nuclear fragmentation in cardiac myocytes, in the absence of E1B. A-C, uninfected cells; D-F, 12 S E1A + E1B; G-I, 12 S E1A - E1B. A, D, and G, phase-contrast microscopy; B, E, and H, sarcomeric MHC immunofluorescence; C, F, and I, Hoechst dye 33258. Cells infected with 12 S E1A + E1B indicate the dependence of cytotoxicity at 48 h on the absence of E1B. Bar, 10 µm. J, DNA laddering induced by 12 S E1A - E1B.





To reexamine transcriptional repression by E1A in this context, cardiac myocytes were subjected to conventional transfection with reporter plasmids, immediately after incubation with virus. Luciferase and lacZ activities were determined 48 h later (Fig. 3A; Table 1). The endogenous cardiac and skeletal alpha-actin genes are co-expressed at this stage in the rat both in vivo(27) and under these conditions of cell culture (18) . Transcription of the skeletal alpha-actin promoter was reduced to 15 ± 2% of control by wild-type 12 S E1A + E1B and was not affected by R2G,C124G + E1B, despite similar levels of E1A protein by Western blot analysis.^2 Mutations that interfere with p300 binding alone (R2G + E1B), or pocket protein binding alone (Y47H,C124G + E1B), retained the ability to repress skeletal actin transcription (27 ± 5% and 16 ± 2%, respectively; p < 0.01 versus control cells). Comparable sensitivity to 12 S E1A + E1B was seen for the cardiac alpha-actin promoter (19 ± 2% of control cells), whereas the cytoplasmic beta-actin and herpes simplex virus thymidine kinase promoters were much less sensitive (50% relative to the control; p < 0.01 for each, versus the sarcomeric alpha-actin promoters).


Figure 3: E1A preferentially represses cardiac-restricted gene transcription (A) and reactivates DNA synthesis in cardiac muscle cells (B). A, luciferase activity is corrected for lacZ (mean ± S.E.) and is expressed relative to that of each promoter, respectively, in uninfected control cells. SkA, skeletal alpha-actin; CaA, cardiac alpha-actin; tk, herpes simplex virus thymidine kinase; betaAc, cytoplasmic beta-actin. B, DNA synthesis was assessed by immunoperoxidase staining for BrdUrd. See Fig. 4for details and representative images. MOI, multiplicity of infection.




Figure 4: E1A-dependent DNA synthesis in cardiac muscle cells. Cells were cultured in serum-free medium, supplemented with 10 µM BrdUrd 44-48 h after exposure to virus. A, uninfected cells; B and G, 12 S E1A + E1B; C, 12 S E1A - E1B; D and H, R2G,C124G + E1B; E, R2G + E1B; F, Y47H,C124G + E1B. A-F, immunoperoxidase detection of BrdUrd. G and H, immunofluorescence confocal microscopy for BrdUrd (fluorescein) and sarcomeric MHC (rhodamine). BrdUrd-positive, MHC-positive cells are seen in panelH. Note the persistence of sarcomeric MHC as a marker of cell identity at this time-point. I, superposition of Hoechst 33258 and MF20 immunofluorescence in cardiac fibroblasts. No sarcomeric MHC was detected. Bar, 50 (A-F) or 20 (G-I) µm.



To determine whether E1A can reactivate DNA synthesis in cardiac muscle cells, and if so, which domains suffice, DNA synthesis was measured by immunoperoxidase staining for BrdUrd (Fig. 3B and 4, A-F; Table 1); preliminary studies with [^3H]thymidine established that maximal DNA synthesis in the ventricular cells occurred 44-48 h after infection with 12 S E1A + E1B.^2 12 S E1A + E1B provoked DNA synthesis between 44 and 48 h in up to 80% of neonatal cells; multiplicities of infection from 20 to 200 did not differ significantly. R2G,C124G + E1B was inactive, whereas mutations that bind either pocket proteins or p300 were both sufficient for DNA synthesis. At 48 h, no increase in cell number was evident, as expected from the fact that the majority of cells were in S phase. No increase in cell number was apparent even at 72 h, regardless of the virus used (except 12 S E1A - E1B, which reduced cell number more than 50%). Hence, E1A was not sufficient to trigger proliferation under these serum-free conditions (cf. (28) ).

To substantiate the conclusion that E1A reactivates DNA synthesis in cardiac myocytes, we performed double immunocytochemistry for sarcomeric MHC and BrdUrd (Fig. 4, G and H). Since myosin staining is excluded from the nucleus (e.g.Fig. 4H), comparing rhodamine and fluorescein fluorescence established for each myosin-positive cell that the BrdUrd-positive nucleus was that of the myocyte itself, not a superimposed fibroblast. Induction of DNA synthesis in cardiac myocytes was confirmed for R2G + E1B and Y47H,C124G + E1B.^2 Thus, cardiac myocytes are susceptible to reinduction of DNA synthesis by each of these complementary E1A proteins. The half-life of cardiac MHCs ranges from 2 to 5 days, depending on the protocol and preparation(29, 30) ; consequently, persistence of MHC protein is not inconsistent with repression of transcription at the time points we studied.

For both transcription repression and reactivation of DNA synthesis, the activity of E1A mutations in cardiac muscle was consistent with operation of two alternative pathways, potentially dependent on pocket proteins and p300, respectively. This interpretation is provisional, as protein-protein interactions are not demonstrated here and differences from other cell types might exist. Preferential inhibition of lineage-specific genes, superimposed on significant but lesser inhibition of nominally constitutive genes, was characteristic of E1A in skeletal muscle as well(6, 31, 32) , concordant with reports of generalized repression by E1A (33) (cf.(4) and (5) ). Although E1A can reportedly sequester the TATA box-binding complex, holo-TFIID(34) , this mechanism is unlikely to account for our results, as the interaction is chiefly mediated by CR3, which is deleted in all 12 S E1A proteins; alternatively, 12 S E1A may also bind TATA-binding protein, weakly by comparison to 13 S E1A(35) . Considering the proposal that transcriptional repression by E1A is mediated by p53 (36) , inhibition of ``constitutive'' promoters may reflect less than complete relief of p53 by our co-expressed E1B gene.

In neonatal cardiac cells, p107 is the predominant pocket protein transcript and is subsequently down-regulated in parallel with p53 (37) ; Rb protein also is expressed in the heart(37) . The corresponding proteins have been presumed to be present at this stage of cardiac maturation. Although the spatial and temporal expression of p300 are unknown, the capacity to bind either pocket proteins or p300 was sufficient in the present study to repress transcription and elicit DNA synthesis in ventricular muscle cells. Thus, the missense mutations employed here perhaps explain the reported need for CR1, yet not CR2, in repression of skeletal muscle-specific genes(4) : deletion of CR1 abrogates binding both to p300 and all known pocket proteins, whereas deletion of CR2 still permits binding to p300(38) . Hence, a p300-dependent pathway may regulate lineage-specific transcription, at least in striated muscle, more generally (cf.(39) ). To our knowledge, the experiments reported here provide the first indication of p300 function in the cardiac muscle lineage. Given that E1A can reactivate DNA synthesis even in terminally differentiated neurons, it will be of interest to the exploit the ability of recombinant adenoviruses to deliver E1A genes to ``post-mitotic'' adult ventricular myocytes(15) .


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grants R01 HL47567, P01 HL49953, and T32 HL07706 (to M. D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Fellow of the Medical Research Council of Canada.

To whom correspondence should be addressed: Molecular Cardiology Unit, One Baylor Plaza, Rm. 506C, Baylor College of Medicine, Houston, TX 77030. Tel.: 713-798-6683; Fax: 713-798-7437.

(^1)
The abbreviations used are: Rb, retinoblastoma gene product; BrdUrd, 5`-bromodeoxyuridine; CR, conserved region; MHC, myosin heavy chain.

(^2)
L. A. Kirshenbaum and M. D. Schneider, unpublished data.


ACKNOWLEDGEMENTS

We are grateful to E. White and E. Moran for the viruses cited, F. Ervin for cell culture, W. Brinkley for generous access to microscopy facilities, R. Scott for expert assistance with microscopy, L. Donehower, H. Epstein, B. French, R. Javier, J. Rosen, and R. Schwartz for comments on the manuscript, and R. Roberts for encouragement and support.


REFERENCES

  1. Nevins, J. R. (1992) Science 258, 424-429 [Medline] [Order article via Infotrieve]
  2. Gu, W., Schneider, J. W., Condorelli, G., Kaushal, S., Mahdavi, V., and Nadal-Ginard, B. (1993) Cell 72, 309-324 [Medline] [Order article via Infotrieve]
  3. Schneider, J. W., Gu, W., Zhu, L., Mahdavi, V., and Nadal-Ginard, B. (1994) Science 264, 1467-1471 [Medline] [Order article via Infotrieve]
  4. Braun, T., Bober, E., and Arnold, H. H. (1992) Genes & Dev. 6, 888-902
  5. Taylor, D. A., Kraus, V. B., Schwarz, J. J., Olson, E. N., and Kraus, W. E. (1993) Mol. Cell. Biol. 13, 4714-4727 [Abstract]
  6. Webster, K. A., Muscat, G. E., and Kedes, L. (1988) Nature 332, 553-557 [CrossRef][Medline] [Order article via Infotrieve]
  7. Moran, E. (1993) FASEB J. 7, 880-885 [Abstract/Free Full Text]
  8. Field, L. J. (1988) Science 239, 1029-1033 [Medline] [Order article via Infotrieve]
  9. Katz, E. B., Steinhelper, M. E., Delcarpio, J. B., Daud, A. I., Claycomb, W. C., and Field, L. J. (1992) Am. J. Physiol. 262, H1867-H1876
  10. DeLeon, J. R., Federoff, H. J., Dickson, D. W., Vikstrom, K. L., and Fishman, G. I. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 519-523 [Abstract]
  11. Ueno, H., Perryman, M. B., Roberts, R., and Schneider, M. D. (1988) J. Cell Biol. 107, 1911-1918 [Abstract]
  12. Whyte, P., Williamson, N. M., and Harlow, E. (1989) Cell 56, 67-75 [Medline] [Order article via Infotrieve]
  13. Wang, H.-G. H., Rikitake, Y., Carter, M. C., Yaciuk, P., Abraham, S. E., Zerler, B., and Moran, E. (1993) J. Virol. 67, 476-488 [Abstract]
  14. Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., Decaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) Genes & Dev. 8, 869-884
  15. Kirshenbaum, L. A., MacLellan, W. R., Mazur, W., French, B. A., and Schneider, M. D. (1993) J. Clin. Invest. 92, 381-387 [Medline] [Order article via Infotrieve]
  16. Brand, T., MacLellan, W. R., and Schneider, M. D. (1993) J. Biol. Chem. 268, 11500-11503 [Abstract/Free Full Text]
  17. Parker, T. G., Chow, K.-L., Schwartz, R. J., and Schneider, M. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7066-7070 [Abstract]
  18. Parker, T. G., Packer, S. E., and Schneider, M. D. (1990) J. Clin. Invest. 85, 507-514 [Medline] [Order article via Infotrieve]
  19. Jones, N., and Shenk, T. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 3665-3669 [Abstract]
  20. Moran, E., Grodzicker, T., Roberts, R. J., Mathews, M. B., and Zerler, B. (1986) Mol. Cell. Biol. 57, 765-775
  21. Chiou, S. K., Tseng, C. C., Rao, L., and White, E. (1994) J. Virol. 68, 6553-6566 [Abstract]
  22. Bader, D., Masaki, T., and Fischman, D. A. (1982) J. Cell Biol. 95, 763-770 [Abstract]
  23. MacLellan, W. R., Lee, T. C., Schwartz, R. J., and Schneider, M. D. (1994) J. Biol. Chem. 269, 16754-16760 [Abstract/Free Full Text]
  24. Abdellatif, M., MacLellan, W. R., and Schneider, M. D. (1994) J. Biol. Chem. 269, 15423-15426 [Abstract/Free Full Text]
  25. Sands, A. T., Hansen, T. N., Demayo, F. J., Stanley, L. A., Xin, L., and Schwartz, R. J. (1993) Mol. Reprod. Dev. 34, 117-126 [Medline] [Order article via Infotrieve]
  26. Rao, L., Debbas, M., Sabbatini, P., Hockenberry, D., Korsmeyer, S., and White, E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7742-7749 [Abstract]
  27. Carrier, L., Boheler, K. R., Chassagne, C., Delabastie, D., Wisnewsky, C., Lakatta, E. G., and Schwartz, K. (1992) Circ. Res. 70, 999-1005 [Abstract]
  28. Sen, D., Dunnmon, P., Henderson, S., Gerard, R. D., and Chien, K. R. (1988) J. Biol. Chem. 263, 19132-19136 [Abstract/Free Full Text]
  29. Martin, A. F., Rabinowitz, M., Blough, R., Prior, G., and Zak, R. (1977) J. Biol. Chem. 252, 3422-9 [Abstract]
  30. Clark, W. A., Jr., and Zak, R. (1981) J. Biol. Chem. 256, 4863-70 [Abstract]
  31. Enkemann, S. A., Konieczny, S. F., and Taparowsky, E. J. (1990) Cell Growth Diff. 1, 375-82 [Abstract]
  32. Mymryk, J. S., Oakes, J. D., Muthuswamy, S. K., Damico, P., and Bayley, S. T. (1992) Biochem. Cell Biol. 70, 1268-1276 [Medline] [Order article via Infotrieve]
  33. Rochette, E. C., Fromental, C., and Chambon, P. (1990) Genes & Dev. 4, 151-155
  34. Boyer, T. G., and Berk, A. J. (1993) Genes & Dev. 7, 1810-1823
  35. Hateboer, G., Timmers, H. M., Rustgi, A. K., Billaud, M., Vantveer, L. J., and Bernards, R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8489-8493 [Abstract/Free Full Text]
  36. Shen, Y. Q., and Shenk, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8940-8944 [Abstract]
  37. Kim, K. K., Soonpaa, M. H., Daud, A. I., Koh, G. Y., Kim, J. S., and Field, L. J. (1994) J. Biol. Chem. 269, 22607-22613 [Abstract/Free Full Text]
  38. Barbeau, D., Charbonneau, R., Whalen, S. G., Bayley, S. T., and Branton, P. E. (1994) Oncogene 9, 359-373 [Medline] [Order article via Infotrieve]
  39. Boulukos, K. E., and Ziff, E. B. (1993) Oncogene 8, 237-248 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.